+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Diabetes Care Devices Market by Type [Diabetes Monitoring (CGM, Test Strips, Self-Monitoring Blood Glucose Meters, Lancets, Haemoglobin A1C Testing Kits)], [Insulin Delivery (Syringes, Pens, Pumps, Jet Injectors)] - Global Forecast to 2028

  • ID: 5516218
  • Report
  • January 2022
  • Region: Global
  • 161 Pages
  • Meticulous Market Research Pvt. Ltd.
Diabetes Care Devices Market by Type [Diabetes Monitoring (CGM, Test Strips, Self-Monitoring Blood Glucose Meters, Lancets, Haemoglobin A1C Testing Kits)], [Insulin Delivery (Syringes, Pens, Pumps, Jet Injectors)] - Global Forecast to 2028

The Diabetes Care Devices Market is expected to grow at a CAGR of 6.7% from 2021 to reach $31.9 billion by 2028.

Succeeding an extensive secondary and primary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities. The growth in the diabetes care devices market is mainly attributed to increased adoption of test strips and self-monitoring blood glucose meters and increasing demand for continuous glucose monitoring with rising awareness towards the disease in developing countries.

The global diabetes care devices market is segmented based on type: (Diabetes Monitoring Devices and Insulin Delivery Devices) and geography (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa). The study also evaluates industry competitors and analyzes their market share at a global level.

Based on type, the diabetes care devices market is segmented into diabetes monitoring devices and insulin delivery devices. In 2021, the diabetes monitoring devices segment is estimated to account for the largest share of the total diabetes care devices market. The growth of diabetes monitoring devices is attributed to the factors such as increased adoption of test strips and self-monitoring blood glucose meters and increasing demand for continuous glucose monitoring with rising awareness towards the disease in developing countries.

Geographically, in 2021, North America is estimated to account for the largest share of the global diabetes care devices market, followed by Europe and Asia-Pacific. Factors such as the increasing prevalence of diabetes with the rising need to self-monitor and treat the disease, increasing prevalence of major risk factors of diabetes such as obesity and sedentary lifestyle, increasing geriatric population, and growing government initiatives promoting diabetes care are driving the growth of the diabetes care devices market in North America. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period

An in-depth analysis of the geographical scenario of the diabetes care devices market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa). In 2021, North America is estimated to account for the largest share of the global diabetes care devices market, followed by Europe and Asia-Pacific.

The key players operating in the global diabetes care devices market are Novo Nordisk A/S (Denmark), Ypsomed AG (Switzerland), Abbott Laboratories (U.S.), Ascensia Diabetes Care Holdings AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), LifeScan IP Holdings, LLC (U.S.), Medtronic PLC (Ireland), Becton, Dickinson and Company (U.S.), Terumo Corporation (Japan), and Sanofi AS (France), Tandem Diabetes Care, Inc. (U.S.), Insulate Corporation (U.S.) and DexCom, Inc. (U.S.)

Scope of the Report:


Global Diabetes Care Devices Market, by Type

  • Diabetes Monitoring Devices
  • Insulin Delivery Devices

Global Diabetes Care Devices Market, by Geography

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
  • China
  • Japan
  • India
  • Rest of APAC (RoAPAC)
  • Latin America
  • Middle East & Africa

Table of Contents

1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-Up Approach
2.3.1.2. Top-Down Approach
2.3.1.3. Growth Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study
3. Executive Summary
4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Increasing Prevalence of Diabetes
4.2.2. Rising Obesity and Prevalence of Disease-Causing Lifestyle
4.2.3. Product Innovations in Diabetes Care
4.2.4. Development of Advanced Insulin Delivery Systems
4.3. Restraints
4.3.1. Insurance Coverage and Reimbursement Scenarios
4.3.2. Product Recalls
4.4. Opportunities
4.4.1. Growing Demand for Non-Invasive Glucose Monitoring Devices
4.5. Challenges
4.5.1. Undiagnosed Diabetes Among Population
4.5.2. Cost of Diabetes Care Devices
4.5.3. Limited Accessibility for Diabetes Care Devices in Low- and Middle-Income Countries
4.6. Regulatory Analysis
4.6.1. North America
4.6.2. Europe
4.6.3. Asia-Pacific
4.7. Impact Assessment of Covid-19 Pandemic on Diabetes Care Devices Market
4.8. Diabetes Patients Population Analysis
4.8.1. Global Diabetes Prevalence
4.8.2. Diabetes Patient Analysis - U.S.
4.8.2.1. Number of Patients - Type 1 Vs Type II (U.S.)
4.8.2.2. Number of Patients Using Monitoring Devices (U.S.)
4.8.2.3. Number of Patients on Insulin Delivery Devices (U.S.)
4.9. Next-Generation Technologies and Solutions for Diabetes Management
4.9.1. Smart Insulin Pens
4.9.2. Closed-Loop Systems
4.9.3. Next Generation CGM Sensors
5. Global Diabetes Care Devices Market, by Type
5.1. Introduction
5.2. Diabetes Monitoring Devices
5.2.1. Test Strips
5.2.2. Continuous Blood Glucose Monitoring Devices
5.2.3. Self-Monitoring Blood Glucose Meters
5.2.4. Hemoglobin A1c Testing Kits
5.2.5. Lancets
5.3. Insulin Delivery Devices
5.3.1. Insulin Pens
5.3.2. Insulin Syringes
5.3.3. Insulin Pumps
5.3.4. Insulin Jet Injectors
6. Diabetes Care Devices Market, by Geography
6.1. Introduction
6.2. North America
6.2.1. U.S.
6.2.2. Canada
6.3. Europe
6.3.1. Germany
6.3.2. France
6.3.3. U.K.
6.3.4. Italy
6.3.5. Spain
6.3.6. Rest of Europe (ROE)
6.4. Asia-Pacific
6.4.1. Japan
6.4.2. China
6.4.3. India
6.4.4. Rest of Asia-Pacific
6.5. Latin America
6.6. Middle East & Africa
7. Competitive Landscape
7.1. Introduction
7.2. Key Growth Strategies
7.3. Competitive Benchmarking
7.4. Market Share Analysis (2020)
7.4.1. Abbott Laboratories (U.S.)
7.4.2. Medtronic PLC (Ireland)
7.4.3. Dexcom, Inc. (U.S.)
7.4.4. F. Hoffmann-La Roche Ltd (Switzerland)
7.5. Diabetes Care Devices Revenue Analysis (2016-2020)
7.5.1. Abbott Laboratories
7.5.2. Medtronic PLC
7.5.3. DexCom, Inc.
7.5.4. F. Hoffmann-La Roche Ltd
7.5.5. LifeScan IP Holdings, LLC
7.5.6. Becton, Dickinson and Company
7.5.7. Insulet Corporation
7.5.8. Novo Nordisk A/S
7.5.9. Tandem Diabetes Care, Inc.
7.5.10. Ypsomed AG
8. Company Profiles
8.1. Abbott Laboratories
8.1.1. Business Overview
8.1.2. Financial Overview
8.1.3. Product Portfolio
8.1.4. Strategic Developments
8.2. Ascensia Diabetes Care Holdings AG (A Part of PHC Holdings Corporation)
8.2.1. Business Overview
8.2.2. Financial Overview
8.2.3. Product Portfolio
8.2.4. Strategic Developments
8.3. Becton, Dickinson and Company
8.3.1. Business Overview
8.3.2. Financial Overview
8.3.3. Product Portfolio
8.4. DexCom, Inc.
8.4.1. Business Overview
8.4.2. Financial Overview
8.4.3. Product Portfolio
8.4.4. Strategic Developments
8.5. F. Hoffmann-La Roche Ltd.
8.5.1. Business Overview
8.5.2. Financialoverview
8.5.3. Product Portfolio
8.5.4. Strategic Developments
8.6. Insulet Corporation
8.6.1. Business Overview
8.6.2. Financial Overview
8.6.3. Product Portfolio
8.6.4. Strategic Developments
8.7. LifeScan IP Holdings, LLC (Subsidiary of Platinum Equity, LLC (U.S.))
8.7.1. Business Overview
8.7.2. Product Portfolio
8.7.3. Strategic Developments
8.8. Medtronic PLC
8.8.1. Business Overview
8.8.2. Financial Overview
8.8.3. Product Portfolio
8.8.4. Strategic Developments
8.9. Novo Nordisk A/S
8.9.1. Business Overview
8.9.2. Financial Overview
8.9.3. Product Portfolio
8.9.4. Strategic Developments
8.10. Sanofi AS
8.10.1. Business Overview
8.10.2. Financial Overview
8.10.3. Product Portfolio
8.10.4. Strategic Developments
8.11. Tandem Diabetes Care, Inc.
8.11.1. Business Overview
8.11.2. Financial Overview
8.11.3. Product Portfolio
8.11.4. Strategic Developments
8.12. Terumo Corporation
8.12.1. Business Overview
8.12.2. Financial Overview
8.12.3. Product Portfolio
8.12.4. Strategic Developments
8.13. Ypsomed AG
8.13.1. Business Overview
8.13.2. Financial Overview
8.13.3. Product Portfolio
8.13.4. Strategic Developments
9. Appendix
9.1. Questionnaire
9.2. Available Customization

Companies Mentioned

  • Novo Nordisk A/S
  • Ypsomed AG
  • Abbott Laboratories
  • Ascensia Diabetes Care Holdings AG
  • F. Hoffmann-La Roche Ltd
  • LifeScan IP Holdings LLC
  • Medtronic PLC
  • Becton Dickinson and Company
  • Terumo Corporation
  • Sanofi AS
  • Tandem Diabetes Care Inc.
  • Insulate Corporation and DexCom Inc. .